What's Happening?
Cancer Cell Diagnostics (CCDx) has announced the commercial launch of its CellSight™ DNA comprehensive genomic profiling test. This innovative test utilizes intact circulating tumor cells (CTCs) from a standard blood draw, rather than the traditional
cell-free circulating tumor DNA fragments. The CellSight™ platform, developed by CCDx, aims to provide a more comprehensive profile of tumor biology by analyzing DNA directly from whole cells. This approach allows for the detection of a wide range of genomic alterations, including single nucleotide variants, insertions, deletions, copy number variations, microsatellite instability (MSI) status, and tumor mutational burden (TMB). The test is performed in CCDx's CLIA-certified laboratory in Jupiter, Florida, and is designed to offer oncologists a more complete molecular understanding of each patient's cancer.
Why It's Important?
The introduction of the CellSight™ DNA test represents a significant advancement in the field of liquid biopsy, offering a potentially more accurate and comprehensive method for cancer diagnosis and monitoring. By utilizing intact circulating tumor cells, the test provides a fuller picture of the tumor's genetic makeup, which can lead to more personalized and effective treatment plans. This innovation could improve patient outcomes by enabling earlier detection of genomic alterations and better tracking of treatment responses. Additionally, the ability to preserve whole cells for future analyses opens up possibilities for further research and development in cancer diagnostics.
